Imophoron has developed the ADDomer™ platform, a patented multimeric protein-based nanoparticle technology that creates highly immunogenic vaccine candidates. This platform aims to provide rapid protection against infectious diseases and generate therapeutic candidates for high unmet medical needs, such as oncology.
Funding
$11M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional vaccine development can be slow and may not always elicit a strong or broadly protective immune response, particularly against rapidly evolving pathogens or in vulnerable populations. Existing vaccine technologies may also struggle to address certain therapeutic areas, such as oncology, where stimulating a targeted immune response against cancer cells is crucial.
Solution
Imophoron is developing novel vaccines and therapeutic candidates based on its proprietary ADDomer™ platform, a protein-based nanoparticle technology designed to enhance immunogenicity. The ADDomer™ platform utilizes a self-assembling, multimeric protein scaffold to display antigens in a highly organized manner, which can lead to improved immune cell activation and a more robust antibody response. This approach aims to provide rapid protection against infectious diseases and generate therapeutic candidates for areas with high unmet medical needs, including oncology. By presenting antigens in a structurally defined and repetitive manner, the ADDomer™ platform seeks to overcome limitations of conventional vaccine approaches and elicit potent, targeted immune responses.
Target Audience
The primary target audience includes pharmaceutical companies and research institutions focused on developing novel vaccines and immunotherapies for infectious diseases and cancer.
Features
- ADDomer™ platform: A patented, multimeric protein-based nanoparticle technology.
- Self-assembling scaffold: Allows for the display of multiple antigens in a highly organized manner.
- Enhanced immunogenicity: Designed to elicit strong and broadly protective immune responses.
- Rapid vaccine development: Aims to accelerate the development of vaccines against emerging infectious diseases.
- Therapeutic applications: Potential to generate therapeutic candidates for oncology and other areas with high unmet medical needs.